Literature DB >> 24912507

Zeb1 promotes androgen independence of prostate cancer via induction of stem cell-like properties.

Ping Li1, Jia Wang2, Mingliang Chu1, Kaiqing Zhang2, Ru Yang1, Wei-Qiang Gao3.   

Abstract

Current androgen deprivation therapy often leads to androgen independence. However, mechanism of the therapeutic failure is still not well understood. Here, we demonstrate elevated expression of Zeb1 in androgen-independent prostate cancer cells and prostate tumors of castrated PTEN conditional knockout mice. While Zeb1 shRNA resulted in a sensitization of androgen-independent prostate cancer cells, forced Zeb1 expression caused androgen-dependent prostate cancer cells to be more resistant to androgen deprivation. Moreover, such effects appeared to be mediated by induction of pluripotent genes or stem cell-like properties. Collectively, these findings suggest that inhibition of Zeb1 might be a potential therapeutic strategy for treatment of androgen-independent prostate cancer.
© 2014 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  Zeb1; androgen-independent prostate cancer; cancer stem cells; epithelial–mesenchymal transition

Year:  2014        PMID: 24912507     DOI: 10.1177/1535370214538727

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  9 in total

Review 1.  EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

Authors:  Rama Soundararajan; Anurag N Paranjape; Sankar Maity; Ana Aparicio; Sendurai A Mani
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-07-05       Impact factor: 10.680

2.  microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1).

Authors:  Guanlin Wu; Jian Wang; Guojun Chen; Xing Zhao
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

3.  Expression of zinc finger E-box-binding homeobox factor 1 in epithelial ovarian cancer: A clinicopathological analysis of 238 patients.

Authors:  Xiufang Li; Ruixia Huang; Ruth Holm Li; Claes G Trope; Jahn M Nesland; Zhenhe Suo
Journal:  Mol Clin Oncol       Date:  2015-10-23

Review 4.  Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer.

Authors:  Galina Gritsina; Wei-Qiang Gao; Jindan Yu
Journal:  Asian J Androl       Date:  2019 May-Jun       Impact factor: 3.285

5.  FOXC2 expression and epithelial-mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer.

Authors:  Astrid Børretzen; Karsten Gravdal; Svein A Haukaas; Christian Beisland; Lars A Akslen; Ole J Halvorsen
Journal:  J Pathol Clin Res       Date:  2019-10-01

6.  Identification of a Zeb1 expressing basal stem cell subpopulation in the prostate.

Authors:  Xue Wang; Haibo Xu; Chaping Cheng; Zhongzhong Ji; Huifang Zhao; Yaru Sheng; Xiaoxia Li; Jinming Wang; Yu Shu; Yuman He; Liancheng Fan; Baijun Dong; Wei Xue; Chee Wai Chua; Dongdong Wu; Wei-Qiang Gao; Helen He Zhu
Journal:  Nat Commun       Date:  2020-02-05       Impact factor: 14.919

7.  Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.

Authors:  A N Paranjape; R Soundararajan; S J Werden; R Joseph; J H Taube; H Liu; J Rodriguez-Canales; N Sphyris; I Wistuba; N Miura; J Dhillon; N Mahajan; K Mahajan; J T Chang; M Ittmann; S N Maity; C Logothetis; D G Tang; S A Mani
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

8.  Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.

Authors:  Chaping Cheng; Zhongzhong Ji; Yaru Sheng; Jinming Wang; Yujiao Sun; Huifang Zhao; Xiaoxia Li; Xue Wang; Yuman He; Jufang Yao; Li Wang; Chenlu Zhang; Yanjing Guo; Jianming Zhang; Wei-Qiang Gao; Helen He Zhu
Journal:  Theranostics       Date:  2018-09-09       Impact factor: 11.556

9.  A SIRT1-centered circuitry regulates breast cancer stemness and metastasis.

Authors:  Lei Shi; Xiaolong Tang; Minxian Qian; Zuojun Liu; Fanbiao Meng; Li Fu; Zimei Wang; Wei-Guo Zhu; Jian-Dong Huang; Zhongjun Zhou; Baohua Liu
Journal:  Oncogene       Date:  2018-07-23       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.